Operator
Welcome to the Q1 2021 Intercept Pharmaceuticals Earnings Call. My name is Anette, and I'll be your operator for today's call. [Operator Instructions]
I will now turn the call over to Lisa DeFrancesco. Lisa, you may begin.
Lisa DeFrancesco --
Senior Vice President of Investor Relations and Corporate Affairs
Thank you. Good morning, and thank you for joining us on today's call. This morning, we issued a press release announcing our first quarter 2021 results and financial position, which is available on our website at www.interceptpharma.com. Before we begin our discussion, I'd like to note that during our call, we will be making forward-looking statements, including statements regarding our approved product and clinical development program; certain regulatory matters; and our strategy, prospects, financial guidance and future commercial and financial performance. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this call. And we undertake no obligation to update such statements, except as required by law. Forward-looking statements are based on estimates and assumptions that, although believed to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. Some, but not necessarily all, of the risk factors that could cause our actual results to differ materially from our historical results or those anticipated or predicted by our forward-looking statements are discussed in this morning's press release and in our periodic public filings with the SEC.